Form 4 for RARE Ultragenyx Pharmaceutical Inc.

Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001209191-22-015833 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2022-03-03	2022-03-01+	RARE	Dier Mardi	CFO, EVP	S - Sale	$65.71	-954	38.2K	-2%	-$62.7K
D	2022-03-03	2022-03-01	RARE	Dier Mardi	CFO, EVP	A - Grant	$0.00	+14.0K	52.2K	+37%	$0
D	2022-03-03	2022-03-01	RARE	Dier Mardi	CFO, EVP	A - Grant	$0.00	+24.9K	24.9K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-03-03	S	D	420	$64.55	51,808	D	—	—	(F4) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
2	Common	Common Stock	2022-03-01	S	D	534	$66.62	38,228	D	—	—
3	Common	Common Stock	2022-03-01	A	A	14,000	$0.00	52,228	D	—	—	(F2) Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
4	Derivative	Stock Option (Right to Buy)	2022-03-01	A	A	24,900	$0.00	24,900	D	$67.37 · — to 2032-03-01	24,900 Common Stock	(F5) On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.